December 11th, 2017

Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will present a corporate overview and host investor meetings at the SVB Securities Global Biopharma Conference and present on Thursday, February 16, 2023, at 12:00 p.m. ET/9:00 a.m. PT.

A live webcast of the presentation will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the live event.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com and follow us on Twitter and LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.90
-2.40 (-1.04%)
AAPL  269.66
-0.04 (-0.01%)
AMD  256.72
-7.61 (-2.88%)
BAC  53.37
+0.79 (1.49%)
GOOG  288.53
+13.36 (4.86%)
META  657.59
-94.08 (-12.52%)
MSFT  527.05
-14.50 (-2.68%)
NVDA  203.27
-3.77 (-1.82%)
ORCL  262.01
-13.29 (-4.83%)
TSLA  443.99
-17.52 (-3.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.